Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (15154)	1/8/2005 4:47:24 AM
From: Icebrg	Read Replies (1) of 52153

>>Looks like plenty of room for Xyotax to improve upon it.>> Yes, no doubt about that. APPX has chosen an interesting approach to their trial. Instead of - as is normally the case - matching the dosing and hoping for at least an improvement in side-effects, they appear to have tried to match the side effects and show a marginal improvement in treatment effects. They have taken out the CREMAFOR-related side-effects, but not much more. I am actually surprised there was an approval here. Maybe this is also the reason for the strong CTIC reaction. The share price was up another 4,5 % after hours. I mean, if FDA can approve on data like Abraxane's, Xyotax should be a slam-dunk, if the survival benefits, which seem to be there, are for real. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next